{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:21:08Z","timestamp":1787066468450,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T00:00:00Z","timestamp":1468886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Science, Sports and Culture","doi-asserted-by":"crossref","award":["21590802"],"award-info":[{"award-number":["21590802"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"name":"P-DIRECT"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s10147-016-1017-6","type":"journal-article","created":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T07:35:41Z","timestamp":1468913741000},"page":"1091-1101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer"],"prefix":"10.1007","volume":"21","author":[{"given":"Xiaofei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Shimodaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Soeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Komine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikashi","family":"Ishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,19]]},"reference":[{"key":"1017_CR1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1126\/science.1191078","volume":"330","author":"R Bonasio","year":"2010","unstructured":"Bonasio R, Tu S, Reinberg D (2010) Molecular signals of epigenetic states. Science 330:612\u2013616","journal-title":"Science"},{"key":"1017_CR2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/carcin\/bgp220","volume":"31","author":"S Sharma","year":"2010","unstructured":"Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31:27\u201336","journal-title":"Carcinogenesis"},{"key":"1017_CR3","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.2010.28.2319","volume":"29","author":"M Engeland van","year":"2011","unstructured":"van Engeland M, Derks S, Smits KM et al (2011) Colorectal cancer epigenetics: complex simplicity. J Clin Oncol 29:1382\u20131391","journal-title":"J Clin Oncol"},{"key":"1017_CR4","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","volume":"358","author":"M Esteller","year":"2008","unstructured":"Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148\u20131159","journal-title":"N Engl J Med"},{"key":"1017_CR5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/ng1834","volume":"38","author":"DJ Weisenberger","year":"2006","unstructured":"Weisenberger DJ, Siegmund KD, Campan M et al (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38:787\u2013793","journal-title":"Nat Genet"},{"key":"1017_CR6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1053\/j.gastro.2005.06.020","volume":"129","author":"WS Samowitz","year":"2005","unstructured":"Samowitz WS, Albertsen H, Herrick J et al (2005) Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129:837\u2013845","journal-title":"Gastroenterology"},{"key":"1017_CR7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2353\/jmoldx.2007.060170","volume":"9","author":"S Ogino","year":"2007","unstructured":"Ogino S, Kawasaki T, Kirkner GJ et al (2007) Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 9:305\u2013314","journal-title":"J Mol Diagn"},{"key":"1017_CR8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/epi.13.4","volume":"5","author":"CP Lange","year":"2013","unstructured":"Lange CP, Laird PW (2013) Clinical applications of DNA methylation biomarkers in colorectal cancer. Epigenomics 5:105\u2013108","journal-title":"Epigenomics"},{"key":"1017_CR9","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.27888","volume":"132","author":"SW Han","year":"2013","unstructured":"Han SW, Lee HJ, Bae JM et al (2013) Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. Int J Cancer 132:2209\u20132216","journal-title":"Int J Cancer"},{"key":"1017_CR10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1053\/j.gastro.2014.05.009","volume":"147","author":"S Shiovitz","year":"2014","unstructured":"Shiovitz S, Bertagnolli MM, Renfro LA et al (2014) CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology 147:637\u2013645","journal-title":"Gastroenterology"},{"key":"1017_CR11","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1053\/j.gastro.2010.12.035","volume":"140","author":"R Jover","year":"2011","unstructured":"Jover R, Nguyen TP, Perez-Carbonell L et al (2011) 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 140:1174\u20131181","journal-title":"Gastroenterology"},{"key":"1017_CR12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229\u2013237","journal-title":"J Clin Oncol"},{"key":"1017_CR13","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040\u20132048","journal-title":"N Engl J Med"},{"key":"1017_CR14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3816\/CCC.2006.n.01","volume":"6","author":"TB Gibson","year":"2006","unstructured":"Gibson TB, Ranganathan A, Grothey A (2006) Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 6:29\u201331","journal-title":"Clin Colorectal Cancer"},{"key":"1017_CR15","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","volume":"66","author":"A Lievre","year":"2006","unstructured":"Lievre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992\u20133995","journal-title":"Cancer Res"},{"key":"1017_CR16","doi-asserted-by":"crossref","unstructured":"Allegra CJ, Rumble RB, Hamilton SR et al (2016) Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015. J Clin Oncol 34:179\u2013185","DOI":"10.1200\/JCO.2015.63.9674"},{"key":"1017_CR17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","volume":"11","author":"W Roock De","year":"2010","unstructured":"De Roock W, Claes B, Bernasconi D et al (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:753\u2013762","journal-title":"Lancet Oncol"},{"key":"1017_CR18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature05933","volume":"448","author":"JD Carpten","year":"2007","unstructured":"Carpten JD, Faber AL, Horn C et al (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439\u2013444","journal-title":"Nature"},{"key":"1017_CR19","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s10147-012-0422-8","volume":"18","author":"H Soeda","year":"2013","unstructured":"Soeda H, Shimodaira H, Watanabe M et al (2013) Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. Int J Clin Oncol 18:670\u2013677","journal-title":"Int J Clin Oncol"},{"key":"1017_CR20","doi-asserted-by":"crossref","first-page":"9821","DOI":"10.1073\/pnas.93.18.9821","volume":"93","author":"JG Herman","year":"1996","unstructured":"Herman JG, Graff JR, Myohanen S et al (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821\u20139826","journal-title":"Proc Natl Acad Sci USA"},{"key":"1017_CR21","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1093\/nar\/28.8.e32","volume":"28","author":"CA Eads","year":"2000","unstructured":"Eads CA, Danenberg KD, Kawakami K et al (2000) MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28:E32","journal-title":"Nucleic Acids Res"},{"key":"1017_CR22","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/gut.2005.082933","volume":"55","author":"S Ogino","year":"2006","unstructured":"Ogino S, Cantor M, Kawasaki T et al (2006) CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 55:1000\u20131006","journal-title":"Gut"},{"key":"1017_CR23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00428-009-0857-0","volume":"455","author":"JH Kim","year":"2009","unstructured":"Kim JH, Shin SH, Kwon HJ et al (2009) Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch 455:485\u2013494","journal-title":"Virchows Arch"},{"key":"1017_CR24","doi-asserted-by":"crossref","first-page":"8541","DOI":"10.1158\/0008-5472.CAN-08-1171","volume":"68","author":"L Barault","year":"2008","unstructured":"Barault L, Charon-Barra C, Jooste V et al (2008) Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res 68:8541\u20138546","journal-title":"Cancer Res"},{"key":"1017_CR25","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s10147-008-0854-3","volume":"13","author":"B Iacopetta","year":"2008","unstructured":"Iacopetta B, Kawakami K, Watanabe T (2008) Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int J Clin Oncol 13:498\u2013503","journal-title":"Int J Clin Oncol"},{"key":"1017_CR26","first-page":"2898","volume":"9","author":"M Rijnsoever Van","year":"2003","unstructured":"Van Rijnsoever M, Elsaleh H, Joseph D et al (2003) CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 9:2898\u20132903","journal-title":"Clin Cancer Res"},{"key":"1017_CR27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/1471-2407-11-344","volume":"11","author":"BH Min","year":"2011","unstructured":"Min BH, Bae JM, Lee EJ et al (2011) The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer 11:344","journal-title":"BMC Cancer"},{"key":"1017_CR28","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/bjc.2011.161","volume":"104","author":"M Scartozzi","year":"2011","unstructured":"Scartozzi M, Bearzi I, Mandolesi A et al (2011) Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br J Cancer 104:1786\u20131790","journal-title":"Br J Cancer"},{"key":"1017_CR29","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/cas.12827","volume":"106","author":"K Ouchi","year":"2015","unstructured":"Ouchi K, Takahashi S, Yamada Y et al (2015) DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer. Cancer Sci 106:1722\u20131729","journal-title":"Cancer Sci"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-016-1017-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-016-1017-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-016-1017-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T14:43:21Z","timestamp":1498315401000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-016-1017-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,19]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1017"],"URL":"https:\/\/doi.org\/10.1007\/s10147-016-1017-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,19]]}}}